PDF herunterladen
Semin Respir Crit Care Med 2020; 41(01): 069-079
DOI: 10.1055/s-0039-3400280
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cryptococcosis

Sofia Zavala
1   Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
,
John W. Baddley
2   Department of Medicine, Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, Alabama
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. Januar 2020 (online)

    Lizenzen und Reprints

Abstract

Cryptococcosis has become an important infection in both immunocompromised and immunocompetent hosts. Although Cryptococcus is mainly recognized by its ability to cause meningoencephalitis, it can infect almost any organ of the human body, with pulmonary infection being the second most common disease manifestation. In cases of meningitis, symptom onset may be insidious, but headaches, fevers, or mental status changes should warrant diagnostic testing. Symptoms of pulmonary disease are nonspecific and may include fever, chills, cough, malaise, night sweats, dyspnea, weight loss, and hemoptysis. Due to protean manifestations of infection, diagnosis may be delayed or misdiagnosis may occur. Diagnosis typically is made by antigen testing of serum or cerebrospinal fluid or by culture or histopathology of infected tissues. A lumbar puncture with the measurement of opening pressure is recommended for patients with suspected or proven cryptococcosis. Treatment of cryptococcosis is based on the anatomical site of disease, severity of disease, and underlying immune status of the patient. Amphotericin B preparations plus 5-flucytosine is used as initial treatment of meningitis, disseminated infection, or moderate-to-severe pulmonary infection followed by fluconazole as a consolidation therapy. Fluconazole is effective for mild-to-moderate pulmonary infection. Important complications include elevated intracranial pressure and immune reconstitution syndrome, which may resemble active disease.

Keywords

Cryptococcus - Cryptococcus neoformans - Cryptococcus gattii - cryptococcosis - pneumonia - fluconazole - amphotericin B - flucytosine
 

  • References

  • 1 Srikanta D, Santiago-Tirado FH, Doering TL. Cryptococcus neoformans: historical curiosity to modern pathogen. Yeast 2014; 31 (02) 47-60
    CrossrefPubMedGoogle Scholar
  • 2 Perfect JR, Dismukes WE, Dromer F. , et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (03) 291-322
    CrossrefPubMedGoogle Scholar
  • 3 Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One 2013; 8 (03) e60431
    CrossrefPubMedGoogle Scholar
  • 4 Rajasingham R, Smith RM, Park BJ. , et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017; 17 (08) 873-881
    CrossrefPubMedGoogle Scholar
  • 5 Jarvis JN, Boulle A, Loyse A. , et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 2009; 23 (09) 1182-1183
    CrossrefPubMedGoogle Scholar
  • 6 Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23 (04) 525-530
    CrossrefPubMedGoogle Scholar
  • 7 Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2016; 30 (01) 179-206
    CrossrefPubMedGoogle Scholar
  • 8 Kwon-Chung KJ, Fraser JA, Doering TL. , et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 2014; 4 (07) a019760
    CrossrefPubMedGoogle Scholar
  • 9 Kwon-Chung KJ, Bennett JE, Wickes BL. , et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. MSphere 2017; 2 (01) 2
    PubMedGoogle Scholar
  • 10 Hagen F, Khayhan K, Theelen B. , et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 2015; 78: 16-48
    CrossrefPubMedGoogle Scholar
  • 11 Hagen F, Lumbsch HT, Arsic Arsenijevic V. , et al. Importance of resolving fungal nomenclature: the case of multiple pathogenic species in the Cryptococcus genus. MSphere 2017; 2 (04) 2
    PubMedGoogle Scholar
  • 12 Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection 2007; 35 (02) 51-58
    CrossrefPubMedGoogle Scholar
  • 13 Emmons CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955; 62 (03) 227-232
    PubMedGoogle Scholar
  • 14 Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991; 13 (06) 1163-1169
    CrossrefPubMedGoogle Scholar
  • 15 Lockhart SR, Iqbal N, Harris JR. , et al. Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates. PLoS One 2013; 8 (09) e74737
    CrossrefPubMedGoogle Scholar
  • 16 Galanis E, Macdougall L, Kidd S, Morshed M. ; British Columbia Cryptococcus gattii Working Group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16 (02) 251-257
    CrossrefPubMedGoogle Scholar
  • 17 Kidd SE, Bach PJ, Hingston AO. , et al. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg Infect Dis 2007; 13 (01) 51-57
    CrossrefPubMedGoogle Scholar
  • 18 Kidd SE, Chow Y, Mak S. , et al. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol 2007; 73 (05) 1433-1443
    CrossrefPubMedGoogle Scholar
  • 19 Kidd SE, Hagen F, Tscharke RL. , et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004; 101 (49) 17258-17263
    CrossrefPubMedGoogle Scholar
  • 20 Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev 2014; 27 (04) 980-1024
    CrossrefPubMedGoogle Scholar
  • 21 Baddley JW, Forrest GN. ; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33 (09) e13543
    PubMedGoogle Scholar
  • 22 Casadevall A, Perfect JR. Cryptococcus Neoformans. Washington, DC: ASM Press; 1998
    Google Scholar
  • 23 Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20 (03) 507-544 , v–vi
    CrossrefPubMedGoogle Scholar
  • 24 Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One 2013; 8 (02) e56269
    CrossrefPubMedGoogle Scholar
  • 25 Saha DC, Goldman DL, Shao X. , et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 2007; 14 (12) 1550-1554
    CrossrefPubMedGoogle Scholar
  • 26 Brunet K, Alanio A, Lortholary O, Rammaert B. Reactivation of dormant/latent fungal infection. J Infect 2018; 77 (06) 463-468
    CrossrefPubMedGoogle Scholar
  • 27 Beyt Jr BE, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978; 298 (15) 825-826
    CrossrefPubMedGoogle Scholar
  • 28 Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med 1985; 313 (04) 266
    PubMedGoogle Scholar
  • 29 Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. ; American Society of Transplantation, Infectious Diseases Community of Practice, Donor-Derived Fungal Infection Working Group. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant 2012; 12 (09) 2414-2428
    CrossrefPubMedGoogle Scholar
  • 30 Sun HY, Alexander BD, Lortholary O. , et al; Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51 (09) 1062-1069
    CrossrefPubMedGoogle Scholar
  • 31 Camargo JF. Donor-derived infections in solid organ transplant recipients: challenging the 30-day paradigm. Transpl Infect Dis 2017; 19 (02) 19
    PubMedGoogle Scholar
  • 32 Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans . Adv Appl Microbiol 2009; 68: 133-216
    PubMedGoogle Scholar
  • 33 Alspaugh JA. Virulence mechanisms and Cryptococcus neoformans pathogenesis. Fungal Genet Biol 2015; 78: 55-58
    CrossrefPubMedGoogle Scholar
  • 34 Doering TL. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans . Annu Rev Microbiol 2009; 63: 223-247
    CrossrefPubMedGoogle Scholar
  • 35 Trevijano-Contador N, Rossi SA, Alves E, Landín-Ferreiroa S, Zaragoza O. Capsule enlargement in Cryptococcus neoformans is dependent on mitochondrial activity. Front Microbiol 2017; 8: 1423
    CrossrefPubMedGoogle Scholar
  • 36 Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 1994; 14 (07) 4912-4919
    CrossrefPubMedGoogle Scholar
  • 37 Wang ZA, Li LX, Doering TL. Unraveling synthesis of the cryptococcal cell wall and capsule. Glycobiology 2018; 28 (10) 719-730
    CrossrefPubMedGoogle Scholar
  • 38 Bouklas T, Pechuan X, Goldman DL, Edelman B, Bergman A, Fries BC. Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. MBio 2013; 4 (04) 4
    CrossrefPubMedGoogle Scholar
  • 39 Bouklas T, Fries BC. Aging: an emergent phenotypic trait that contributes to the virulence of Cryptococcus neoformans . Future Microbiol 2015; 10 (02) 191-197
    CrossrefPubMedGoogle Scholar
  • 40 Gish SR, Maier EJ, Haynes BC. , et al. Computational analysis reveals a key regulator of cryptococcal virulence and determinant of host response. MBio 2016; 7 (02) e00313-e00316
    PubMedGoogle Scholar
  • 41 Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61 (01) 146-149
    CrossrefPubMedGoogle Scholar
  • 42 Gassiep I, Douglas J, Emeto TI, Crawley K, Playford EG. Cryptococcal infections over a 15 year period at a tertiary facility & impact of guideline management. Mycoses 2018; 61 (09) 633-638
    CrossrefPubMedGoogle Scholar
  • 43 Saag MS, Graybill RJ, Larsen RA. , et al; Infectious Diseases Society of America. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30 (04) 710-718
    CrossrefPubMedGoogle Scholar
  • 44 Graybill JR, Sobel J, Saag M. , et al; The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000; 30 (01) 47-54
    CrossrefPubMedGoogle Scholar
  • 45 Baddley JW, Thompson III GR, Riley KO, Moore MK, Moser SA, Pappas PG. Factors associated with ventriculoperitoneal shunt placement in patients with cryptococcal meningitis. Open Forum Infect Dis 2019; 6 (06) ofz241
    CrossrefPubMedGoogle Scholar
  • 46 Choe YH, Moon H, Park SJ. , et al. Pulmonary cryptococcosis in asymptomatic immunocompetent hosts. Scand J Infect Dis 2009; 41 (08) 602-607
    CrossrefPubMedGoogle Scholar
  • 47 Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2008; 29 (02) 141-150
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 48 Brizendine KD, Baddley JW, Pappas PG. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2011; 32 (06) 727-734
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 49 Ye F, Xie JX, Zeng QS, Chen GQ, Zhong SQ, Zhong NS. Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Hai 2012; 190 (03) 339-346
    PubMedGoogle Scholar
  • 50 He Q, Ding Y, Zhou W. , et al. Clinical features of pulmonary cryptococcosis among patients with different levels of peripheral blood CD4+ T lymphocyte counts. BMC Infect Dis 2017; 17 (01) 768
    CrossrefPubMedGoogle Scholar
  • 51 Kohno S, Kakeya H, Izumikawa K. , et al. Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. J Infect Chemother 2015; 21: 23-30
    CrossrefPubMedGoogle Scholar
  • 52 Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 2003; 124 (06) 2143-2147
    CrossrefPubMedGoogle Scholar
  • 53 Deng H, Zhang J, Li J, Wang D, Pan L, Xue X. Clinical features and radiological characteristics of pulmonary cryptococcosis. J Int Med Res 2018; 46 (07) 2687-2695
    PubMedGoogle Scholar
  • 54 Chang WC, Tzao C, Hsu HH. , et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129 (02) 333-340
    CrossrefPubMedGoogle Scholar
  • 55 Lomes NR, Melhem MS, Szeszs MW, Martins MdosA, Buccheri R. Cryptococcosis in non-HIV/non-transplant patients: a Brazilian case series. Med Mycol 2016; 54 (07) 669-676
    CrossrefPubMedGoogle Scholar
  • 56 Chau TT, Mai NH, Phu NH. , et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis 2010; 10: 199
    CrossrefPubMedGoogle Scholar
  • 57 Walraven CJ, Gerstein W, Hardison SE. , et al. Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS One 2011; 6 (12) e28625
    CrossrefPubMedGoogle Scholar
  • 58 Patil RT, Sangwan J, Juyal D, Lathwal S. Meningitis due to Cryptococcus gattii in an immunocompetent patient. J Clin Diagn Res 2013; 7 (10) 2274-2275
    PubMedGoogle Scholar
  • 59 Baddley JW, Perfect JR, Oster RA. , et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27 (10) 937-943
    CrossrefPubMedGoogle Scholar
  • 60 Chechani V, Kamholz SL. Pulmonary manifestations of disseminated cryptococcosis in patients with AIDS. Chest 1990; 98 (05) 1060-1066
    CrossrefPubMedGoogle Scholar
  • 61 Rozenbaum R, Gonçalves AJ. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994; 18 (03) 369-380
    CrossrefPubMedGoogle Scholar
  • 62 Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991; 13 (01) 64-67
    CrossrefPubMedGoogle Scholar
  • 63 Meyohas MC, Roux P, Bollens D. , et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995; 21 (03) 628-633
    CrossrefPubMedGoogle Scholar
  • 64 Visnegarwala F, Graviss EA, Lacke CE. , et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998; 27 (05) 1231-1237
    CrossrefPubMedGoogle Scholar
  • 65 Akilimali NA, Muema DM, Specht C. , et al. Cryptococcosis-associated immune reconstitution inflammatory syndrome is associated with dysregulation of IL-7/IL-7 receptor signaling pathway in T cells and monocyte activation. J Acquir Immune Defic Syndr 2019; 80 (05) 596-604
    CrossrefPubMedGoogle Scholar
  • 66 Siddiqui TJ, Zamani T, Parada JP. Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient. J Infect 2005; 51 (03) e153-e157
    CrossrefPubMedGoogle Scholar
  • 67 Lanternier F, Chandesris MO, Poirée S. , et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7 (12) 2826-2828
    CrossrefPubMedGoogle Scholar
  • 68 Sun HY, Alexander BD, Lortholary O. , et al; Cryptococcal Collaborative Transplant Study Group. Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol 2010; 48 (06) 785-791
    CrossrefPubMedGoogle Scholar
  • 69 Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O. ; French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36 (03) 337-347
    CrossrefPubMedGoogle Scholar
  • 70 Malabonga VM, Basti J, Kamholz SL. Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS. Chest 1991; 99 (02) 370-372
    CrossrefPubMedGoogle Scholar
  • 71 Gazzoni AF, Severo CB, Salles EF, Severo LC. Histopathology, serology and cultures in the diagnosis of cryptococcosis. Rev Inst Med Trop São Paulo 2009; 51 (05) 255-259
    CrossrefPubMedGoogle Scholar
  • 72 Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL, Wengenack NL. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol 2009; 47 (11) 3669-3672
    CrossrefPubMedGoogle Scholar
  • 73 Boulware DR, Rolfes MA, Rajasingham R. , et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 2014; 20 (01) 45-53
    CrossrefPubMedGoogle Scholar
  • 74 Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol 2015; 78: 49-54
    CrossrefPubMedGoogle Scholar
  • 75 Vidal JE, Boulware DR. Lateral flow assay for cryptococcal antigen: an important advance to improve the continuum of HIV care and reduce cryptococcal meningitis-related mortality. Rev Inst Med Trop São Paulo 2015; 57 (Suppl. 19) 38-45
    CrossrefPubMedGoogle Scholar
  • 76 Lourens A, Jarvis JN, Meintjes G, Samuel CM. Rapid diagnosis of cryptococcal meningitis by use of lateral flow assay on cerebrospinal fluid samples: influence of the high-dose “hook” effect. J Clin Microbiol 2014; 52 (12) 4172-4175
    CrossrefPubMedGoogle Scholar
  • 77 Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32 (07) 1680-1684
    CrossrefPubMedGoogle Scholar
  • 78 Singh N, Alexander BD, Lortholary O. , et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46 (02) e12-e18
    PubMedGoogle Scholar
  • 79 Pappas PG, Perfect JR, Cloud GA. , et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33 (05) 690-699
    CrossrefPubMedGoogle Scholar
  • 80 Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115 (03) 734-740
    CrossrefPubMedGoogle Scholar
  • 81 Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. Am Rev Respir Dis 1992; 145 (05) 1226-1229
    CrossrefPubMedGoogle Scholar
  • 82 Kralovic SM, Rhodes JC. Utility of routine testing of bronchoalveolar lavage fluid for cryptococcal antigen. J Clin Microbiol 1998; 36 (10) 3088-3089
    CrossrefPubMedGoogle Scholar
  • 83 Leber AL, Everhart K, Balada-Llasat JM. , et al. Multicenter evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016; 54 (09) 2251-2261
    CrossrefPubMedGoogle Scholar
  • 84 Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Susceptibility Testing of Yeasts. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017
    Google Scholar
  • 85 Thompson III GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibility among different serotypes of Cryptococcus gattii and Cryptococcus neoformans . Antimicrob Agents Chemother 2009; 53 (01) 309-301
    CrossrefPubMedGoogle Scholar
  • 86 Gast CE, Basso Jr LR, Bruzual I, Wong B. Azole resistance in Cryptococcus gattii from the Pacific Northwest: investigation of the role of ERG11. Antimicrob Agents Chemother 2013; 57 (11) 5478-5485
    CrossrefPubMedGoogle Scholar
  • 87 Forrest GN, Bhalla P, DeBess EE. , et al. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases. Transpl Infect Dis 2015; 17 (03) 467-476
    CrossrefPubMedGoogle Scholar
  • 88 Lahiri Mukhopadhyay S, Bahubali VH, Manjunath N. , et al. Central nervous system infection due to Cryptococcus gattii sensu lato in India: analysis of clinical features, molecular profile and antifungal susceptibility. Mycoses 2017; 60 (11) 749-757
    CrossrefPubMedGoogle Scholar
  • 89 Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Medicine (Baltimore) 1998; 77 (01) 50-58
    PubMedGoogle Scholar
  • 90 Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5 (03) 140-143
    CrossrefPubMedGoogle Scholar
  • 91 McMullan BJ, Sorrell TC, Chen SC. Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. Future Microbiol 2013; 8 (12) 1613-1631
    CrossrefPubMedGoogle Scholar
  • 92 Zinck SE, Leung AN, Frost M, Berry GJ, Müller NL. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr 2002; 26 (03) 330-334
    CrossrefPubMedGoogle Scholar
  • 93 Khoury MB, Godwin JD, Ravin CE, Gallis HA, Halvorsen RA, Putman CE. Thoracic cryptococcosis: immunologic competence and radiologic appearance. AJR Am J Roentgenol 1984; 142 (05) 893-896
    CrossrefPubMedGoogle Scholar
  • 94 Xie LX, Chen YS, Liu SY, Shi YX. Pulmonary cryptococcosis: comparison of CT findings in immunocompetent and immunocompromised patients. Acta Radiol 2015; 56 (04) 447-453
    CrossrefPubMedGoogle Scholar
  • 95 Yang R, Yan Y, Wang Y, Liu X, Su X. Plain and contrast-enhanced chest computed tomography scan findings of pulmonary cryptococcosis in immunocompetent patients. Exp Ther Med 2017; 14 (05) 4417-4424
    PubMedGoogle Scholar
  • 96 Yang CJ, Hwang JJ, Wang TH. , et al. Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients. Scand J Infect Dis 2006; 38 (09) 788-793
    CrossrefPubMedGoogle Scholar
  • 97 Roebuck DJ, Fisher DA, Currie BJ. Cryptococcosis in HIV negative patients: findings on chest radiography. Thorax 1998; 53 (07) 554-557
    CrossrefPubMedGoogle Scholar
  • 98 Igai H, Gotoh M, Yokomise H. Computed tomography (CT) and positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg 2006; 30 (06) 837-839
    CrossrefPubMedGoogle Scholar
  • 99 Wang SY, Chen G, Luo DL. , et al. 18F-FDG PET/CT and contrast-enhanced CT findings of pulmonary cryptococcosis. Eur J Radiol 2017; 89: 140-148
    CrossrefPubMedGoogle Scholar
  • 100 Harris JR, Lockhart SR, Debess E. , et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53 (12) 1188-1195
    CrossrefPubMedGoogle Scholar
  • 101 Bennett JE, Dismukes WE, Duma RJ. , et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979; 301 (03) 126-131
    CrossrefPubMedGoogle Scholar
  • 102 O'Connor L, Livermore J, Sharp AD. , et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis 2013; 208 (02) 351-361
    CrossrefPubMedGoogle Scholar
  • 103 van der Horst CM, Saag MS, Cloud GA. , et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337 (01) 15-21
    CrossrefPubMedGoogle Scholar
  • 104 Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. ; French Cryptococcosis Study Group. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008; 3 (08) e2870
    CrossrefPubMedGoogle Scholar
  • 105 Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40 (03) 480-482
    CrossrefPubMedGoogle Scholar
  • 106 Rolfes MA, Hullsiek KH, Rhein J. , et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis 2014; 59 (11) 1607-1614
    CrossrefPubMedGoogle Scholar
  • 107 Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40 (03) 477-479
    CrossrefPubMedGoogle Scholar
  • 108 Corti M, Priarone M, Negroni R. , et al. Ventriculoperitoneal shunts for treating increased intracranial pressure in cryptococcal meningitis with or without ventriculomegaly. Rev Soc Bras Med Trop 2014; 47 (04) 524-527
    CrossrefPubMedGoogle Scholar
  • 109 Saag MS, Cloud GA, Graybill JR. , et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28 (02) 291-296
    CrossrefPubMedGoogle Scholar
  • 110 Esposito V, Viglietti R, Gargiulo M. , et al. Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. In Vivo 2009; 23 (03) 465-468
    PubMedGoogle Scholar
  • 111 Alexander BD, Perfect JR, Daly JS. , et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86 (06) 791-796
    CrossrefPubMedGoogle Scholar
  • 112 Raad II, Graybill JR, Bustamante AB. , et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42 (12) 1726-1734
    CrossrefPubMedGoogle Scholar
  • 113 Clark NM, Grim SA, Lynch III JP. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med 2015; 36 (05) 767-785
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 114 Perfect JR, Marr KA, Walsh TJ. , et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36 (09) 1122-1131
    CrossrefPubMedGoogle Scholar
  • 115 Sabbatani S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004; 158 (02) 165-171
    CrossrefPubMedGoogle Scholar
  • 116 Yao Y, Zhang JT, Yan B. , et al. Voriconazole: a novel treatment option for cryptococcal meningitis. Infect Dis (Lond) 2015; 47 (10) 694-700
    CrossrefPubMedGoogle Scholar
  • 117 Thompson III GR, Rendon A, Ribeiro Dos Santos R. , et al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis 2016; 63 (03) 356-362
    CrossrefPubMedGoogle Scholar
  • 118 Vibhagool A, Sungkanuparph S, Mootsikapun P. , et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36 (10) 1329-1331
    CrossrefPubMedGoogle Scholar
  • 119 Mussini C, Pezzotti P, Miró JM. , et al; International Working Group on Cryptococcosis. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38 (04) 565-571
    CrossrefPubMedGoogle Scholar
  • 120 Singh N, Lortholary O, Alexander BD. , et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80 (08) 1033-1039
    CrossrefPubMedGoogle Scholar
  • 121 Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. Adv Exp Med Biol 2008; 635: 135-146
    PubMedGoogle Scholar
  • 122 Singh N, Lortholary O, Alexander BD. , et al; Cryptococcal Collaborative Transplant Study Group. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40 (12) 1756-1761
    CrossrefPubMedGoogle Scholar
  • 123 Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35 (12) e128-e133
    CrossrefPubMedGoogle Scholar
  • 124 Trevenzoli M, Cattelan AM, Rea F. , et al. Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 2002; 45 (03) 173-179
    CrossrefPubMedGoogle Scholar
  • 125 Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005; 51 (05) e289-e297
    CrossrefPubMedGoogle Scholar
  • 126 Boulware DR, Bonham SC, Meya DB. , et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202 (06) 962-970
    CrossrefPubMedGoogle Scholar
  • 127 Chang CC, Lim A, Omarjee S. , et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208 (06) 898-906
    CrossrefPubMedGoogle Scholar
  • 128 Williamson PR, Jarvis JN, Panackal AA. , et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol 2017; 13 (01) 13-24
    PubMedGoogle Scholar
  • 129 Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7 (06) 395-401
    CrossrefPubMedGoogle Scholar
  • 130 McKinsey DS, Wheat LJ, Cloud GA. , et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999; 28 (05) 1049-1056
    CrossrefPubMedGoogle Scholar
  • 131 Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. Cochrane Database Syst Rev 2018; 8: CD004773
    PubMedGoogle Scholar
  • 132 Temfack E, Kouanfack C, Mossiang L. , et al. Cryptococcal antigen screening in asymptomatic HIV-infected antiretroviral naïve patients in Cameroon and evaluation of the new semi-quantitative Biosynex CryptoPS test. Front Microbiol 2018; 9: 409
    CrossrefPubMedGoogle Scholar